Zacks Investment Research upgraded Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to Hold in a report released today.
- Updated: October 11, 2016
Zacks Investment Research has upgraded Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to Hold in a report released on 10/11/2016.
Just yesterday Anthera Pharmaceuticals Inc (NASDAQ:ANTH) traded -2.49% lower at $3.13. Anthera Pharmaceuticals Inc’s 50-day moving average is $3.10 and its 200-day moving average is $3.34. The last stock price is down -6.35% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 280,793 shares of ANTH traded hands, down from an average trading volume of 462,486
Recent Performance Chart
Anthera Pharmaceuticals Inc has 52 week low of $2.28 and a 52 week high of $7.15 and has a market capitalization of $0.
Brief Synopsis On Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.